313 related articles for article (PubMed ID: 32183301)
41. Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.
Hastak K; Bhutra S; Parry R; Ford JM
Oncotarget; 2017 Apr; 8(16):26344-26355. PubMed ID: 28412751
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
[TBL] [Abstract][Full Text] [Related]
43. XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.
Ali R; Alblihy A; Toss MS; Algethami M; Al Sunni R; Green AR; Rakha EA; Madhusudan S
Ther Adv Med Oncol; 2020; 12():1758835920974201. PubMed ID: 33425022
[TBL] [Abstract][Full Text] [Related]
44. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
45. PARP inhibitors: A new era of targeted therapy.
Tangutoori S; Baldwin P; Sridhar S
Maturitas; 2015 May; 81(1):5-9. PubMed ID: 25708226
[TBL] [Abstract][Full Text] [Related]
46. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
47. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
48. DNA Repair Inhibitors Potentiate Fractionated Radiotherapy More Than Single-Dose Radiotherapy in Breast Cancer Cells.
Wong WK; Guerra Liberal FDC; McMahon SJ
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954456
[TBL] [Abstract][Full Text] [Related]
49. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
50. PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials.
Kamel D; Gray C; Walia JS; Kumar V
Curr Drug Targets; 2018; 19(1):21-37. PubMed ID: 28699513
[TBL] [Abstract][Full Text] [Related]
51. Current status of poly(ADP-ribose) polymerase inhibitors and future directions.
Ohmoto A; Yachida S
Onco Targets Ther; 2017; 10():5195-5208. PubMed ID: 29138572
[TBL] [Abstract][Full Text] [Related]
52. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
53. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
[TBL] [Abstract][Full Text] [Related]
54. LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors.
Wang YS; Chen J; Cui F; Wang H; Wang S; Hang W; Zeng Q; Quan CS; Zhai YX; Wang JW; Shen XF; Jian YP; Zhao RX; Werle KD; Cui R; Liang J; Li YL; Xu ZX
Oncotarget; 2016 Nov; 7(45):73389-73401. PubMed ID: 27705915
[TBL] [Abstract][Full Text] [Related]
55. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
[TBL] [Abstract][Full Text] [Related]
56. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
McCann KE
Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451
[TBL] [Abstract][Full Text] [Related]
57. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
58. PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session.
Patel R; Fein D; Ramirez CB; Do K; Saif MW
Pancreas (Fairfax); 2019; 3(1):e5-e8. PubMed ID: 32030362
[TBL] [Abstract][Full Text] [Related]
59. Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models.
Karmokar A; Sargeant R; Hughes AM; Baakza H; Wilson Z; Talbot S; Bloomfield S; Leo E; Jones GN; Likhatcheva M; Tobalina L; Dean E; Cadogan EB; Lau A
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627223
[TBL] [Abstract][Full Text] [Related]
60. PARP Inhibitors in Prostate and Urothelial Cancers.
Garje R; Vaddepally RK; Zakharia Y
Front Oncol; 2020; 10():114. PubMed ID: 32117762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]